Day: March 23, 2021

Boston, Massachusetts, March 22, 2021 (GLOBE NEWSWIRE) — ArcLight Clean Transition Corp. II (the “Company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced the pricing of its upsized initial public offering of 27,500,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Capital Market and trade under the ticker symbol “ACTDU” beginning March 23, 2021. Each unit consists of one Class A ordinary share of the Company and one-fifth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on...

GUANGZHOU, China, March 23, 2021 (GLOBE NEWSWIRE) — Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that the record date for its upcoming quarterly cash dividend for the fourth quarter of 2020 will be changed from the previously announced March 31, 2020 to March 31, 2021. The payment date for the cash dividend will be changed from on and around April 15, 2020 to April 15, 2021. The dividend amount of US$0.25 per ADS, or US$0.0125 remains unchanged. The dividends to be paid to the ADS holders through the depositary bank will be subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. About Fanhua Inc. Fanhua Inc. is a leading independent financial services provider. Through our online platforms and offline...

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares to be sold in the offering are to be sold by Exagen. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $60.1 million. In addition, Exagen has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock. The offering is expected to close on or about March 25, 2021, subject to the satisfaction of customary closing conditions. Exagen intends to use the net proceeds from the proposed offering for the...

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten public offering of 2,033,899 shares of its common stock at a price to the public of $14.75 per share. In addition, Verrica has granted to the underwriters a 30-day option to purchase up to 305,084 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Verrica are expected to be approximately $30.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters’ option. The offering is expected to close on or about March...

Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at MedytoxJUPITER, Fla., March 22, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs...

AIRPORT CITY, Israel, March 22, 2021 (GLOBE NEWSWIRE) — My Size, Inc. (the “Company” or “My Size”) (NASDAQ: MYSZ) (TASE: MYSZ), the developer and creator of e-commerce measurement solutions, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.3 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The proposed offering equates to 2,618,532 shares of the Company’s common stock at a price of $1.26 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The Company has also granted the underwriters a 45-day option to purchase up to an additional 15% of the number of shares of common stock offered in...

TORONTO, March 22, 2021 (GLOBE NEWSWIRE) — Mount Logan Capital Inc. (NEO: MLC) (“Mount Logan,” “our,” “we,” or the “Company”) announces its financial results for the year ended December 31, 2020. All amounts are stated in United States dollars, unless otherwise indicated. Highlights:In the fourth quarter, Mount Logan accelerated its transition to a fee-driven business by completing its transaction with Sierra Crest Investment Management LLC (“Sierra Crest”) related to the Alternative Credit Income Fund (“CIF”), acquired a minority stake in Sierra Crest, a U.S. asset management platform, and closed its acquisition of management contracts for a U.S. collateralized loan obligation platform (the “CLO Platform”). In connection with these activities, in the fourth quarter, Mount Logan began recognizing management fee and other income. Total...